On March 6–7, the "2026 In Vivo CAR‑T Deep Dive Workshop," co‑hosted by Enorna, TONACEA, and other organizations, was successfully held in Shanghai. The workshop focused on the industrialization of in vivo CAR‑T, bringing together academic experts, industry pioneers, and investors from both viral and non‑viral delivery fields. Participants engaged in practical and in‑depth discussions on core topics including R&D innovation, CMC challenges, IND applications, and clinical translation.

As an RNA/LNP CRDMO, Enorna empowers its customers from early‑stage R&D to commercial production with robust platform technologies and process development capabilities. Throughout the two‑day conference, Enorna’s booth remained highly popular. Visitors from pharmaceutical companies, biotech firms, and research institutions engaged in deep discussions with our technical team on topics such as antibody conjugation processes, LNP formulation design, scale‑up strategies, and IND filing experience.

From ADC to Antibody‑Conjugated LNP – Delivery Systems Define the Future of Nucleic Acid Drugs

On the morning of the first day, Dr. Zihui Fang, Founder and CEO of Enorna, not only served as the forum moderator but also delivered a keynote presentation titled "From In Vivo CAR‑T to Next‑Generation Antibody‑Conjugated Drugs: Breaking Through CMC Bottlenecks."

Dr. Fang systematically explained the advantages of antibody‑conjugation technology for precision targeted delivery in drug R&D, drawing from the perspective of ADCs. He pointed out that the success of ADCs has validated the clinical and commercial value of the "antibody guidance + effector molecule" model. As the effector molecule expands from small‑molecule toxins to nucleic acids, XDC has formally entered a new era: Avidity’s AOC 1001 has advanced into Phase III clinical trials, validating the technical feasibility of antibody‑mediated extrahepatic delivery of nucleic acids.

In the future, innovative drugs will follow a "rocket + warhead" development trend. As nucleic acid drugs become more diversified and continue to develop, delivery systems will also drive the future evolution of nucleic acid therapeutics.

Antibody‑conjugated LNPs are designed precisely to address these challenges – integrating the precision targeting capability of antibodies with the efficient delivery mechanism of LNPs. In vivo CAR‑T – antibody‑conjugated LNPs targeting T cells – represents a cutting‑edge application of this platform technology in immunotherapy.

He then shared data on Enorna's antibody‑conjugated tLNP platform capabilities for in vivo CAR‑T applications:

• High‑efficiency and highly adaptable platform: 

The platform has been successfully applied to both full‑length IgG and VHH nanobodies, achieving high conjugation efficiency while maintaining stable particle size, PDI, and encapsulation efficiency.

• Process scale‑up validated: 

Key quality attributes remain stable from laboratory scale to pilot scale.

• Single‑particle characterization system: 

Nanoparticle flow cytometry provides a high‑resolution, multi‑parameter, high‑throughput solution at the single‑particle level.

From a broader perspective, in vivo CAR‑T is just the beginning: the same delivery platform can carry diverse payloads such as mRNA, siRNA, and gene‑editing tools, target different tissues including T cells, tumor cells, and muscle cells, and be applied to a wide range of indications such as oncology, autoimmune diseases, rare diseases, and metabolic disorders. A powerful delivery system can address core challenges across multiple fields. Antibody‑conjugated LNPs will define the future of nucleic acid drugs.

The Journey Goes Further with Partners

Though the workshop was brief, the shared exploration, resonance, thoughts, and connections will continue to grow. Enorna will continue to deepen its focus on the antibody‑conjugated LNP delivery system and work alongside industry partners to drive nucleic acid in vivo therapies from technological breakthroughs to true industrial application.

In this early spring season, our sincere thanks go to every colleague who joined us. Next time, we look forward to sharing more progress and reflections with you.

About Enorna

Enorna Biotechonlogy is an mRNA CRDMO company powered by proprietary LNP delivery technology and integrated IP platforms. We deliver end-to-end solutions from sequence design to commercial manufacturing. True to our mission of building the nucleic therapeutics ecosystem for global patient access, we are dedicated to becoming the world's industrialization powerhouse—driving the nucleic therapeutics revolution to ensure these life-changing medicines reach patients everywhere.